SNCA and Parkinson disease: We studied the effect of the Rep1 variant as well as other PD risk-associated variants on SNCA-mRNA steady state levels in vivo in three human brain structures differentially vulnerable to PD; i.e. frontal cortex, temporal cortex and mid-brain including the substantia nigra (SN).